KHPG(SZ:002773) Zheng Quan Zhi Xing·2025-08-27 16:41Core Viewpoint - Chengdu Kanghong Pharmaceutical Group Co., Ltd. has decided to cancel part of the stock options from the 2021 stock option incentive plan due to certain incentive objects not meeting the exercise conditions [1][5][12]. Summary by Sections 1. Overview of the 2021 Stock Option Incentive Plan - The company held a board meeting on August 27, 2025, to review and approve the cancellation of certain stock options from the 2021 stock option incentive plan [1]. - The plan was initially approved with specific procedures and independent opinions from the board [1][2]. 2. Adjustments to the Incentive Plan - The number of incentive objects was adjusted from 421 to 410, and the total number of stock options granted was reduced from 12.805 million to 12.07 million [3]. - The exercise price for the stock options was adjusted multiple times, with the latest being set at 21.05 yuan per share for the first grant and 13.84 yuan per share for reserved grants [6][9]. 3. Cancellation of Stock Options - A total of 524,300 stock options were canceled due to various reasons, including failure to meet performance criteria and non-exercise of options by certain incentive objects [12][13]. - The cancellation process was deemed compliant with the company's incentive plan and relevant laws [13][14]. 4. Impact on the Company - The cancellation of stock options is not expected to significantly impact the company's financial status or operational results, nor will it affect the motivation and stability of the management team [12][13]. 5. Opinions from Committees - The Compensation and Assessment Committee and the Supervisory Board both agreed that the cancellation of stock options aligns with the company's incentive plan and legal regulations [12][13].